Liquid biopsy in breast cancer: current biomarker platforms and clinical applications

Abstract

Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and despite considerable advances in therapeutic strategies, the absence of reliable, minimally invasive diagnostic tools continues to limit early detection and real-time disease monitoring. Liquid biopsy has emerged as a transformative paradigm in oncology, offering the capacity to integrate tumor biology through the analysis of tumor-derived materials that circulate in peripheral blood and other biofluids. This review provides a comprehensive overview of the key analytes employed in liquid biopsy, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), microRNAs (miRNAs), extracellular vesicles (EVs), and protein biomarkers with particular emphasis on their translational relevance in breast cancer. Drawing on landmark clinical trials and foundational molecular studies, we highlight how these biomarkers capture spatial and temporal tumor heterogeneity in ways that conventional tissue biopsy cannot. Finally, we address the technical, clinical, and ethical challenges that still impede widespread adoption of liquid biopsy, and we outline a forward-looking research agenda oriented toward multi-omics integration and point-of-care diagnostics. Taken together, this review underscores the potential of liquid biopsy to complement existing diagnostic standards and improve how we screen for, monitor, and treat breast cancer across disease stages.

Keywords

liquid biopsy / breast cancer / circulating tumor DNA / extracellular vesicles / microRNA / circulating tumor cells / precision medicine / biosensor

References

[1] Watkins EJ. Overview of breast cancer. JAAPA. 2019; 32: 13-7.

[2] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66: 15-23.

[3] Parker AL, Benguigui M, Fornetti J, Goddard E, Lucotti S, Insua-Rodríguez J, et al. Current challenges in metastasis research and future innovation for clinical translation. Clin Exp Metastasis. 2022; 39: 263-77.

[4] Batis N, Brooks JM, Payne K, Sharma N, Nankivell P, Mehanna H. Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Adv Drug Deliv Rev. 2021; 176: 113854.

[5] Cleland J, Azam F, Midgley R, Kerr DJ. Biomarkers in Oncology. Princ Transl Sci Med. 2015; 185-8.

[6] Gilson P, Merlin JL, Harlé A. Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy. Cancers. 2022; 14: 1384.

[7] Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025; 25: 613-33.

[8] Singh S, Podder PS, Russo M, Henry C, Cinti S. Tailored point-of-care biosensors for liquid biopsy in the field of oncology. Lab Chip. 2023; 23: 44-61.

[9] Wang H, Zhang Y, Zhang H, Cao H, Mao J, Chen X, et al. Liquid biopsy for human cancer: cancer screening, monitoring, and treatment. MedComm. 2024; 5: e564.

[10] Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024; 9: 336.

[11] Kalligosfyri PM, Miglione A, Raucci A, Cimmino W, Iula G, Glovi A, et al. Multifunctional biosensors redefining liquid biopsy: advancing simultaneous multianalyte detection. Trends Biotechnol. 2026.

[12] Singh S, Kalligosfyri PM, Miglione A, Raucci A, Glovi A, Iula G, et al. Point-of-Care testing: an ally for precision oncology. Ann Res Oncol. 2025; 05: 116.

[13] Kalligosfyri PM, Cinti S. Paper-Based Materials for Diagnostics. ACS Mater Lett. 2024; 6: 1184-98.

[14] Cimmino W, Angelillo A, Kalligosfyri PM, Nele V, Campani V, Carbone S, et al. Multiplex Detection and Quantification of miRNAs in Drug Delivery Systems Using a Signal-Off Electrochemical Platform. Anal Chem. 2026; 98: 13211-9.

[15] Singh S, Raucci A, Glovi A, Iula G, Mutti L, De Laurentiis M, et al. Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system. Cancer Metastasis Rev. 2025; 44: 64.

[16] Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023; 22: 7.

[17] Adhit KK, Wanjari A, Menon S, K S. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine. Cureus. 2023; 15: e50176.

[18] Chenchula S, Paraskar G, Krishna S, Chavan M. Liquid biopsy in clinical practice: current evidence and future directions. Liq biopsy Cancer Manag. 2026; 405-38.

[19] Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, et al. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021; 9: 89-110.

[20] Strobl MAR, Gallaher J, Robertson-Tessi M, West J, Anderson ARA. Treatment of evolving cancers will require dynamic decision support. Ann Oncol. 2023; 34: 867-84.

[21] Chang CM, Lam HYP. Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies. Anticancer Res. 2023; 43: 5283-98.

[22] Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021; 23: 85.

[23] Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7: 313ra182.

[24] Wu TM, Liu JB, Liu Y, Shi Y, Li W, Wang GR, et al. Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control. Cancer Control. 2020; 27: 1073274820934805.

[25] Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2020; 207: 107458.

[26] Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023; 21: 118.

[27] Tan CR, Zhou L, El-Deiry WS. Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Curr Colorectal Cancer Rep. 2016; 12: 151-61.

[28] Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, et al. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res. 2019; 25: 3581-8.

[29] Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, et al. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin Chem. 2017; 63: 691-9.

[30] Kim MW, Park S, Lee H, Gwak H, Hyun KA, Kim JY, et al. Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer. Cancer Sci. 2021; 112: 5078-87.

[31] Wu HJ, Chu PY. Current and Developing Liquid Biopsy Techniques for Breast Cancer. Cancers. 2022; 14: 2052.

[32] Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl J Med. 2013; 368: 1199-209.

[33] McKay C, Rahman T, Ghimire B, Girgis M. Circulating Tumor DNA in Breast Cancer: Diagnostic Insights From a Case Series. Cureus. 2026; 18: e100833.

[34] Nader-Marta G, Monteforte M, Agostinetto E, Cinquini M, Martins-Branco D, Langouo M, et al. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. 2024; 9: 102390.

[35] Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Int J Mol Sci. 2022; 23: 9006.

[36] Malik S, Zaheer S. The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology. J Liq Biopsy. 2025; 8: 100299.

[37] Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10: e10.

[38] Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology. 2020; 31: 745-59.

[39] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.

[40] Ranganathan K, Sivasankar V. MicroRNAs-Biology and clinical applications. J Oral Maxillofac Pathol. 2014; 18: 229-34.

[41] Moro G, Fratte CD, Normanno N, Polo F, Cinti S. Point-of-Care Testing for the Detection of MicroRNAs: Towards Liquid Biopsy on a Chip. Angew Chem Int Ed. 2023; 62: e202309135.

[42] Singh S, Glovi A, De Laurentiis M, Cinti S. A novel point-of-care device for monitoring circulating miRNA-107 in prostate cancer: towards a user-friendly liquid biopsy. Ann Res Oncol. 2025; 05: 95.

[43] Glovi A, Kalligosfyri PM, Miglione A, Singh S, Iula G, Giordano A, et al. Towards liquid biopsy on chip for Triple Negative Breast Cancer: preliminary results on monitoring circulating miRNA-21 using portable diagnostics. Discov Oncol. 2025; 16: 1022.

[44] Kisiel JB, Ebbert JO, Taylor WR, Marinac CR, Choudhry OA, Rego SP, et al. Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing. Life. 2024; 14: 925.

[45] Han J, Jiang Y, Zhang C, Yang Y, Pang D, Song Y, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 2017; 92: 55.

[46] Al-Khanbashi M, Al-Moundhri M. Micro-ribonucleic acid and carcinogenesis: breast cancer as an example. Oncol Rev. 2015; 9: 279.

[47] Marbán É. The Secret Life of Exosomes. J Am Coll Cardiol. 2018; 71: 193-200.

[48] Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X. Current Strategies for Exosome Cargo Loading and Targeting Delivery. Cells. 2023; 12: 1416.

[49] Huang LB, Kong C, Yang MF, Zhang S, Yue NN, Zhang Y, et al. Apoptotic vesicles: from biological characteristics to clinical translational prospects. J Transl Med. 2026; 24: 235.

[50] Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, et al. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018; 16: 179.

[51] Jiang N, Saftics A, Romano E, Ghaeli I, Resto C, Robles V, et al. Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy. J Nanobiotechnology. 2024; 22: 589.

[52] Riethdorf S, Soave A, Rink M. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Transl Androl Urol. 2017; 6: 1090-110.

[53] Salu P, Reindl KM. Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications. Cancers. 2024; 16: 1213.

[54] Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11: 858-73.

[55] Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: A Prognostic Marker in Breast Cancer. Int J Biol Markers. 2000; 15: 330-3.

[56] Singh S, Glovi A, Miglione A, Cimmino W, Iula G, Antonelli L, et al. Electrochemical (bio)sensors for cancer therapy monitoring. Electrochim Acta. 2025; 537: 146929.

[57] Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023; 41: 1091-102.e4.

[58] Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570: 385-9.

[59] Ignatiadis M, Lee M, Jeffrey SS. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res. 2015; 21: 4786-800.

[60] Xie S, Wang Y, Gong Z, Li Y, Yang W, Liu G, et al. Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients. J Cancer. 2022; 13: 744-51.

[61] Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, et al.; PADA-1 investigators. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022; 23: 1367-77.

[62] Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025; 393: 569-80.

[63] Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, et al. Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncol. 2021; 7: 34-41.